CA2920946A1 - Materials and methods relating to pancreatic cancer - Google Patents

Materials and methods relating to pancreatic cancer Download PDF

Info

Publication number
CA2920946A1
CA2920946A1 CA2920946A CA2920946A CA2920946A1 CA 2920946 A1 CA2920946 A1 CA 2920946A1 CA 2920946 A CA2920946 A CA 2920946A CA 2920946 A CA2920946 A CA 2920946A CA 2920946 A1 CA2920946 A1 CA 2920946A1
Authority
CA
Canada
Prior art keywords
tumor
pancreatic
protein
proteins
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2920946A
Other languages
English (en)
French (fr)
Inventor
Zen YOH
Nigel Heaton
Alberto Quaglia
David Britton
Malcolm Ward
Ian Pike
Vikram MITRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Kings College Hospital NHS Foundation Trust
Original Assignee
Electrophoretics Ltd
Kings College Hospital NHS Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd, Kings College Hospital NHS Foundation Trust filed Critical Electrophoretics Ltd
Publication of CA2920946A1 publication Critical patent/CA2920946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
CA2920946A 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer Abandoned CA2920946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1314485.2 2013-08-13
GBGB1314485.2A GB201314485D0 (en) 2013-08-13 2013-08-13 Materials and methods relating to pancreatic cancer
PCT/GB2014/052475 WO2015022530A2 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Publications (1)

Publication Number Publication Date
CA2920946A1 true CA2920946A1 (en) 2015-02-19

Family

ID=49262110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920946A Abandoned CA2920946A1 (en) 2013-08-13 2014-08-13 Materials and methods relating to pancreatic cancer

Country Status (7)

Country Link
US (1) US20160195536A1 (https=)
EP (1) EP3033624A2 (https=)
JP (1) JP2016535270A (https=)
CN (1) CN105637367A (https=)
CA (1) CA2920946A1 (https=)
GB (1) GB201314485D0 (https=)
WO (1) WO2015022530A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
JP2020514684A (ja) * 2016-12-20 2020-05-21 トリート４ライフ アーベー 質量分析によってｂｒａｆ突然変異および野生型ｂｒａｆタンパク質を定める方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
JPWO2022154037A1 (https=) * 2021-01-14 2022-07-21

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE102006056784A1 (de) * 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
EP2391891A1 (en) * 2009-01-27 2011-12-07 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
WO2011092338A1 (en) * 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
CN102947706B (zh) * 2010-04-19 2018-04-13 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
AU2011260390B2 (en) * 2010-06-01 2016-11-24 Ernst-Moritz-Arndt Universitat Greifswald Means and methods for diagnosing pancreatic cancer in a subject
EP2582727B8 (en) * 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
US20140222443A1 (en) * 2011-06-07 2014-08-07 Kathleen Danenberg Molecular profiling for cancer

Also Published As

Publication number Publication date
EP3033624A2 (en) 2016-06-22
JP2016535270A (ja) 2016-11-10
WO2015022530A3 (en) 2015-04-09
WO2015022530A2 (en) 2015-02-19
US20160195536A1 (en) 2016-07-07
GB201314485D0 (en) 2013-09-25
CN105637367A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
Old et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma
US20160195536A1 (en) Materials and Methods Relating to Pancreatic Cancer
Lucarelli et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml
Tan et al. Cancer proteomics
Britton et al. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets
Thinon et al. Global profiling of co-and post-translationally N-myristoylated proteomes in human cells
Mikula et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors
US10768182B2 (en) Method for detecting nucleosomes containing histone modifications and variants
Schrödter et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
JP5406187B2 (ja) 前立腺癌の代謝プロファイリング法
Lou et al. Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non–small cell lung cancer and its potential as a circulating biomarker
Sharma et al. Multipronged quantitative proteomic analyses indicate modulation of various signal transduction pathways in human meningiomas
JP2015500478A (ja) ヌクレオソームアダクト検出法
Omenn et al. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications
WO2014116833A2 (en) Compositions and methods for detecting neoplasia
Abe et al. Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens
Pan et al. Ubiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7
Jiang et al. iTRAQ‐based quantitative proteomics approach identifies novel diagnostic biomarkers that were essential for glutamine metabolism and redox homeostasis for gastric cancer
Chaker et al. Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas
Pavlou et al. Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer
Wu et al. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues
Sun et al. From clinic to mechanism: Proteomics‐based assessment of angiogenesis in adrenal pheochromocytoma
Yang et al. Quantitative analysis of differential proteome expression in bladder cancer vs. normal bladder cells using SILAC method
Cui et al. TRIM37 augments AP-2γ transcriptional activity and cellular localization via K63-linked ubiquitination to drive breast cancer progression
Xiao et al. Cyclin B2 overexpression promotes tumour growth by regulating jagged 1 in hepatocellular carcinoma

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831